Gilead Science took a bad hit when their bet on a medical trial failed. Subsequently, their stock price has come down considerably. But, the company is still profitable and is very focused on growth ahead. Also, market forces should easily push the stock price higher than where it is when looked at from a price-to-earnings ratio. For that matter, by any matrix, the stock is cheap and should go higher.
Valuation Drivers Correlation
|Investment Horizon||30 Days Login to change|